Correlation of disease characteristics with CD33 expression levels
| Category . | All cases . | CD33 MFI ratio . | |||
|---|---|---|---|---|---|
| n = 621 . | Lower third . | Middle third . | Upper third . | P . | |
| CD 33 MFI ratio | |||||
| Median (range) | 57 (1-456) | 11 (1-30) | 57 (30-94) | 157 (94-456) | |
| Age, y | .01 | ||||
| Median (range) | 57 (17-99) | 57 (19-99) | 59 (17-82) | 53 (18-89) | |
| Gender, n (%) | .13 | ||||
| Male | 337 (54%) | 124 (60%) | 108 (52%) | 105 (51%) | |
| Female | 284 (46%) | 83 (40%) | 99 (48%) | 102 (49%) | |
| FAB, n (%) | <.001 | ||||
| M0 | 29 (5%) | 15 (8%) | 11 (6%) | 3 (2%) | |
| M1 | 114 (21%) | 41 (22%) | 40 (22%) | 33 (18%) | |
| M2 | 174 (32%) | 80 (44%) | 53 (30%) | 41 (22%) | |
| M4 | 153 (28%) | 26 (14%) | 53 (30%) | 74 (40%) | |
| M5 | 61 (11%) | 10 (6%) | 19 (11%) | 32 (17%) | |
| M6 / M7 | 16 (3%) | 11 (6%) | 3 (2%) | 2 (1%) | |
| Unknown | 74 | 24 | 28 | 22 | |
| Cytogenetics, n (%) | |||||
| t(8;21) | 31 (5%) | 26 (13%) | 4 (2%) | 1 (<1%) | <.001 |
| inv(16)/t(16;16)(p13;q22) | 40 (7%) | 11 (5%) | 18 (9%) | 11 (5%) | .24 |
| Normal karyotype | 312 (52%) | 83 (41%) | 108 (54%) | 121 (60%) | <.001 |
| t(9;11)(p21-22;q23) or t(11;19)(q23;p13) | 22 (4%) | 2 (1%) | 7 (4%) | 13 (6%) | .01 |
| Abnormalities not classified as favorable or adverse | 102 (17%) | 39 (19%) | 26 (13%) | 37 (18%) | .21 |
| Complex karyotype | 55 (9%) | 30 (15%) | 19 (10%) | 6 (3%) | <.001 |
| Other adverse risk abnormalities* | 43 (7%) | 13 (6%) | 17 (9%) | 13 (6%) | .63 |
| Unknown | 16 | 3 | 8 | 5 | |
| Cytogenetic risk group, n (%) | <.001 | ||||
| Favorable | 71 (12%) | 37 (18%) | 22 (11%) | 12 (6%) | |
| Intermediate | 436 (72%) | 124 (61%) | 141 (71%) | 171 (85%) | |
| Adverse | 98 (16%) | 43 (21%) | 36 (18%) | 19 (9%) | |
| Mutations, n (%) | |||||
| NPM1+/FLT3-ITD− (normal karyotype) | 97 (16%) | 16 (8%) | 34 (17%) | 47 (23%) | <.001 |
| NPM1+/FLT3-ITD+ (normal karyotype) | 69 (11%) | 12 (6%) | 27 (14%) | 30 (15%) | .009 |
| NPM1−/FLT3-ITD+ (normal karyotype) | 34 (6%) | 9 (4%) | 11 (6%) | 14 (7%) | .54 |
| NPM1−/FLT3-ITD− (normal karyotype) | 112 (19%) | 46 (23%) | 36 (18%) | 30 (15%) | .13 |
| ELN, n (%) | .14 | ||||
| Favorable | 181 (32%) | 64 (33%) | 57 (31%) | 60 (31%) | |
| Intermediate-I | 169 (30%) | 48 (24%) | 59 (32%) | 62 (32%) | |
| Intermediate-II | 115 (20%) | 40 (20%) | 31 (17%) | 44 (23%) | |
| Adverse | 107 (19%) | 44 (22%) | 38 (21%) | 25 (13%) | |
| Unknown | 49 | 11 | 22 | 16 | |
| Category . | All cases . | CD33 MFI ratio . | |||
|---|---|---|---|---|---|
| n = 621 . | Lower third . | Middle third . | Upper third . | P . | |
| CD 33 MFI ratio | |||||
| Median (range) | 57 (1-456) | 11 (1-30) | 57 (30-94) | 157 (94-456) | |
| Age, y | .01 | ||||
| Median (range) | 57 (17-99) | 57 (19-99) | 59 (17-82) | 53 (18-89) | |
| Gender, n (%) | .13 | ||||
| Male | 337 (54%) | 124 (60%) | 108 (52%) | 105 (51%) | |
| Female | 284 (46%) | 83 (40%) | 99 (48%) | 102 (49%) | |
| FAB, n (%) | <.001 | ||||
| M0 | 29 (5%) | 15 (8%) | 11 (6%) | 3 (2%) | |
| M1 | 114 (21%) | 41 (22%) | 40 (22%) | 33 (18%) | |
| M2 | 174 (32%) | 80 (44%) | 53 (30%) | 41 (22%) | |
| M4 | 153 (28%) | 26 (14%) | 53 (30%) | 74 (40%) | |
| M5 | 61 (11%) | 10 (6%) | 19 (11%) | 32 (17%) | |
| M6 / M7 | 16 (3%) | 11 (6%) | 3 (2%) | 2 (1%) | |
| Unknown | 74 | 24 | 28 | 22 | |
| Cytogenetics, n (%) | |||||
| t(8;21) | 31 (5%) | 26 (13%) | 4 (2%) | 1 (<1%) | <.001 |
| inv(16)/t(16;16)(p13;q22) | 40 (7%) | 11 (5%) | 18 (9%) | 11 (5%) | .24 |
| Normal karyotype | 312 (52%) | 83 (41%) | 108 (54%) | 121 (60%) | <.001 |
| t(9;11)(p21-22;q23) or t(11;19)(q23;p13) | 22 (4%) | 2 (1%) | 7 (4%) | 13 (6%) | .01 |
| Abnormalities not classified as favorable or adverse | 102 (17%) | 39 (19%) | 26 (13%) | 37 (18%) | .21 |
| Complex karyotype | 55 (9%) | 30 (15%) | 19 (10%) | 6 (3%) | <.001 |
| Other adverse risk abnormalities* | 43 (7%) | 13 (6%) | 17 (9%) | 13 (6%) | .63 |
| Unknown | 16 | 3 | 8 | 5 | |
| Cytogenetic risk group, n (%) | <.001 | ||||
| Favorable | 71 (12%) | 37 (18%) | 22 (11%) | 12 (6%) | |
| Intermediate | 436 (72%) | 124 (61%) | 141 (71%) | 171 (85%) | |
| Adverse | 98 (16%) | 43 (21%) | 36 (18%) | 19 (9%) | |
| Mutations, n (%) | |||||
| NPM1+/FLT3-ITD− (normal karyotype) | 97 (16%) | 16 (8%) | 34 (17%) | 47 (23%) | <.001 |
| NPM1+/FLT3-ITD+ (normal karyotype) | 69 (11%) | 12 (6%) | 27 (14%) | 30 (15%) | .009 |
| NPM1−/FLT3-ITD+ (normal karyotype) | 34 (6%) | 9 (4%) | 11 (6%) | 14 (7%) | .54 |
| NPM1−/FLT3-ITD− (normal karyotype) | 112 (19%) | 46 (23%) | 36 (18%) | 30 (15%) | .13 |
| ELN, n (%) | .14 | ||||
| Favorable | 181 (32%) | 64 (33%) | 57 (31%) | 60 (31%) | |
| Intermediate-I | 169 (30%) | 48 (24%) | 59 (32%) | 62 (32%) | |
| Intermediate-II | 115 (20%) | 40 (20%) | 31 (17%) | 44 (23%) | |
| Adverse | 107 (19%) | 44 (22%) | 38 (21%) | 25 (13%) | |
| Unknown | 49 | 11 | 22 | 16 | |
Including abn(3q), inv(3)(q21q26)/t(3;3)(q21;q26), add(5q), −5/5q-, −7, add(7q)/del(7q), t(v;11)(v;q23), t(9;22)(q34;q11), −17/abn(17p), but excluding t(3;5)(q21∼25;q31∼35), t(9;11)(p21-22;q23) and t(11;19)(q23;p13).